A U.S. district court memorandum held claims in US Patent No. 11,634,752 (owned by Scale Biosciences/10x Genomics) invalid for lack of written description and enablement after Parse Biosciences challenged the patent in litigation. The decision removes a legal barrier for instrument‑free split‑pool single‑cell sequencing competitors and may reshape patent tactics in the single‑cell space. 10x/Scale have other asserted patents; the ruling could influence ongoing disputes and licensing strategies across single‑cell platforms.